Veterinary Medicines

GLETVAX-6 ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ

Authorised
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium perfringens, type B and C, beta toxoid
  • Escherichia coli, fimbrial adhesin F6
  • Escherichia coli, fimbrial adhesin F5
  • Escherichia coli, fimbrial adhesin F4ac
  • Escherichia coli, fimbrial adhesin F4ab
Download as PDF

Product identification

Medicine name:
GLETVAX-6 ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ
Active substance:
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium perfringens, type B and C, beta toxoid
  • Escherichia coli, fimbrial adhesin F6
  • Escherichia coli, fimbrial adhesin F5
  • Escherichia coli, fimbrial adhesin F4ac
  • Escherichia coli, fimbrial adhesin F4ab
Target species:
  • Pig
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Clostridium perfringens, type D, epsilon toxoid
    40.00
    international unit(s)
    /
    5.00
    millilitre(s)
  • Clostridium perfringens, type B and C, beta toxoid
    60.00
    international unit(s)
    /
    5.00
    millilitre(s)
  • Escherichia coli, fimbrial adhesin F6
    20.00
    unit(s)
    /
    5.00
    millilitre(s)
  • Escherichia coli, fimbrial adhesin F5
    20.00
    unit(s)
    /
    5.00
    millilitre(s)
  • Escherichia coli, fimbrial adhesin F4ac
    20.00
    unit(s)
    /
    5.00
    millilitre(s)
  • Escherichia coli, fimbrial adhesin F4ab
    20.00
    unit(s)
    /
    5.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        0
        day
  • Subcutaneous use
    • Pig
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AB08
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Available in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • Zoetis Hellas S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 56934/08-09-2008/K-0097201
Date of authorisation status change: